BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 18275039)

  • 1. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O; Syha Y; Zettl H; Kock M; Bock A; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2008 Mar; 341(3):191-5. PubMed ID: 18275039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists.
    Popescu L; Rau O; Böttcher J; Syha Y; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2007 Jul; 340(7):367-71. PubMed ID: 17610302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
    Thieme TM; Steri R; Proschak E; Paulke A; Schneider G; Schubert-Zsilavecz M
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2469-73. PubMed ID: 20307981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle.
    Benton CR; Koonen DP; Calles-Escandon J; Tandon NN; Glatz JF; Luiken JJ; Heikkila JJ; Bonen A
    J Physiol; 2006 May; 573(Pt 1):199-210. PubMed ID: 16484294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
    Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
    J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver.
    Wierzbicki M; Chabowski A; Zendzian-Piotrowska M; Gorski J
    J Physiol Pharmacol; 2009 Mar; 60(1):99-106. PubMed ID: 19439812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
    J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.
    Lanne B; Dahllöf B; Lindahl C; Ebefors K; Kanmert I; von Bahr H; Miliotis T; Nyström AC; Arnerup G; Paulsons I; Kerb S; Oakes N
    J Proteome Res; 2006 Aug; 5(8):1850-9. PubMed ID: 16889406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ
    J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor alpha but not gamma activators.
    Yeh CH; Chen TP; Lee CH; Wu YC; Lin YM; Lin PJ
    Shock; 2006 Sep; 26(3):262-70. PubMed ID: 16912651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα.
    Lamers C; Dittrich M; Steri R; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem Lett; 2014 Aug; 24(16):4048-52. PubMed ID: 25022880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
    Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
    Kasuga J; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2006 Feb; 16(3):554-8. PubMed ID: 16275077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity.
    Fracchiolla G; Laghezza A; Piemontese L; Carbonara G; Lavecchia A; Tortorella P; Crestani M; Novellino E; Loiodice F
    ChemMedChem; 2007 May; 2(5):641-54. PubMed ID: 17357171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.